EMS Healthcare secures a major deal with US clinical research partner
EMS Healthcare, the UK’s largest mobile clinical research partner, today announced a partnership with US-based EmVenio Research, with the aim of conducting commercial clinical trials via a network of mobile sites.Keith Austin
Published 20 June 2023
It is EmVenio’s first international venture and their expansion into the UK will utilise EMS Healthcare’s expertise in delivering clinical trials with greater diverse participation via the use of mobile clinics.
The collaboration will allow EmVenio to garner a wider demographic of research participants and diversify its clinical trial offerings, based on the needs of pharmaceutical sponsors, and could also have a positive impact on health outcomes in the UK.
Keith Henthorne, CEO of EmVenio, said: “People living in underserved communities often have limited time and access to participate in potential life-improving clinical trials, often leaving a gap in research studies. EMS have proven experience of delivering care and conducting research in the heart of communities, removing barriers and accelerating trials – all of which aligns with our goals. With their support, we are now able to expand our footprint across the UK and increase the diversity of clinical trial participation to reflect the population more accurately.”
EMS Healthcare has identified 10 potential mobile site locations, each to be supported by a dedicated local workforce. EmVenio will be responsible for full clinical oversight, along with all clinical trial operations and data management.
Keith Austin, CEO of EMS Healthcare, said: “We are delighted to be partnering with EmVenio on this exciting development for clinical trials in the UK. A recent independent review of commercial clinical trials by Lord James O’Shaughnessy acknowledged the crucial role of mobile clinics in carrying out trials with more diverse participation. We believe this initiative will attract more pharmaceutical sponsors to carry out trials, which will have a significant impact on both the economy and the health of our population.”
And Mr Austin added: “I can absolutely envisage other partnerships of a similar nature in the future – it’s vital that we all work together to ensure that we support clinical trial sponsors in reaching underserved communities.”
EmVenio currently operates clinical research programmes in 10 mobile community sites across the United States. The first site in this country will be in operation in the coming months.